An international phase 3 clinical trial found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.
A new targeted treatment shows promise for select patients with stomach cancer
